ReviewDiabetology & metabolic syndrome2025
Prevalence and impact of microvascular complications in type 2 diabetes mellitus on cognitive impairment and depression: a systematic review and meta-analysis.
Review in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Essential micronutrients and biguanides (metformin) synergistic and antagonistic interactions on neurocognitive outcomes in type two diabetes mellitus: a systematic review of preclinical and clinical evidence.Frontiers in endocrinology · 2026Pooled it
- Prevalence, risk factors, and early prediction of cognitive impairment in patients with diabetes mellitus: a systematic review and meta-analysis.Frontiers in endocrinology · 2026Pooled it
- Mapping the evolution of botanical interventions for diabetic neuropathy: a two-database bibliometric landscape from 2005 to mid-2025.Frontiers in nutrition · 2025Pooled it
- Applications of Continuous Glucose Monitoring in Cognitive Research in Diabetes: a Scoping Review.Current diabetes reports · 2026Article
- Review
- Exosome-mediated cell-cell communication: a new perspective on the mechanisms and therapeutic potential of diabetic microvascular complications.Frontiers in pharmacology · 2026Review
- Ketogenic metabolic therapy: low-carbohydrate interventions as novel neuroprotective strategies for cognitive dysfunction in diabetes.Frontiers in aging neuroscience · 2026Review
- Anthocyanins Modulation of Gut Microbiota to Reverse Obesity-Driven Inflammation and Insulin Resistance.Nutrients · 2025Review
- Review
- Different association between triglyceride-glucose index and mild cognitive impairment in type 2 diabetes mellitus patients with and without diabetic kidney disease.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes mellitus (T2DM) is a global health burden, often leading to microvascular complications such as neuropathy, retinopathy, and nephropathy. These complications may contribute to cognitive impairment and depression, further complicating disease management and adversely affecting quality of life. This systematic review and meta-analysis aimed to assess the prevalence and association between diabetic microvascular complications and cognitive impairment and depression among individuals with T2DM.
methodsA systematic search of PubMed, Embase, and Web of Science was conducted through November 15, 2024, following PRISMA guidelines. Observational studies examining the association between microvascular complications and mental health outcomes were included. Study quality was assessed using the Methodological Index for Non-Randomized Studies (MINORS) scale. Meta-analyses were performed using standard statistical software, with pooled odds ratios (ORs) and 95% confidence intervals (CIs) calculated.
resultsOut of 5,640 articles screened, 7 studies met inclusion criteria. The prevalence of cognitive impairment was 34.9% in patients with neuropathy, 55.29% with retinopathy, and 40.97% with nephropathy. Depression prevalence was 43.30% for neuropathy, 40.17% for retinopathy, and 18.92% for nephropathy. Associations with cognitive impairment showed ORs of 0.878 (95% CI, 0.298-2.585) for neuropathy, 1.358 (95% CI, 0.957-1.927) for retinopathy, and 1.421 (95% CI, 1.086-1.858) for nephropathy. For depression, ORs were 1.291 (95% CI, 0.613-2.721) for retinopathy and 6.200 (95% CI, 0.029-1305.771) for neuropathy.
conclusionMicrovascular complications in T2DM contribute substantially to the burden of cognitive impairment and depression, with nephropathy showing a particularly strong link to cognitive decline. Standardized assessment approaches are needed, and integrated mental health care should be prioritized in the management of individuals with diabetes. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.